ストックスクリーナーアプリを入手
218.89
1.02%
-2.26
アフターアワーズ：
218.89
前日終値:
$221.15
開ける：
$221.66
24時間の取引高:
879.82K
Relative Volume:
0.65
時価総額：
$31.58B
収益：
$5.54B
当期純損益:
$1.52B
株価収益率:
21.10
EPS:
10.3734
ネットキャッシュフロー:
$1.74B
1週間 パフォーマンス:
-1.40%
1か月 パフォーマンス:
-5.19%
6か月 パフォーマンス:
-2.32%
1年 パフォーマンス:
-20.88%
1日の値動き範囲:
$218.03
$223.73
1週間の範囲:
$218.03
$224.22
52週間の値動き範囲:
$180.26
$284.87
Resmed Inc Stock (RMD) Company Profile
Compare RMD vs ISRG, BDX, MDLN, ALC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
218.89 | 32.02B | 5.54B | 1.52B | 1.74B | 10.37 |
ISRG
Intuitive Surgical Inc
|
391.95 | 143.14B | 11.03B | 3.16B | 3.22B | 8.7251 |
BDX
Becton Dickinson Co
|
176.80 | 50.07B | 21.37B | 1.41B | 3.07B | 3.9437 |
MDLN
Medline Inc
|
35.61 | 30.44B | 29.14B | 1.07B | 1.05B | 1.1956 |
ALC
Alcon Inc
|
63.76 | 31.16B | 10.63B | 819.00M | 1.59B | 1.6577 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-15 | 開始されました | JP Morgan | Overweight |
| 2025-12-16 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2025-09-18 | 開始されました | Citigroup | Buy |
| 2025-09-02 | アップグレード | CLSA | Hold → Outperform |
| 2025-07-15 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-03-19 | 開始されました | Morgan Stanley | Overweight |
| 2025-01-16 | 開始されました | Goldman | Buy |
| 2025-01-10 | 開始されました | Piper Sandler | Neutral |
| 2024-12-13 | 開始されました | Stifel | Hold |
| 2024-09-24 | 開始されました | Robert W. Baird | Outperform |
| 2024-09-18 | ダウングレード | Wolfe Research | Peer Perform → Underperform |
| 2024-09-04 | ダウングレード | Needham | Buy → Hold |
| 2024-06-25 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2024-06-24 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-02-06 | 再開されました | KeyBanc Capital Markets | Overweight |
| 2023-10-27 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-12 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-10-09 | アップグレード | JP Morgan | Neutral → Overweight |
| 2023-09-29 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2023-09-06 | アップグレード | Needham | Hold → Buy |
| 2023-09-05 | ダウングレード | UBS | Buy → Neutral |
| 2023-08-01 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-05-23 | 開始されました | UBS | Buy |
| 2023-04-14 | 開始されました | Mizuho | Buy |
| 2023-01-17 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-10-28 | ダウングレード | Citigroup | Buy → Neutral |
| 2022-10-20 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-10-12 | 開始されました | Jefferies | Hold |
| 2022-09-08 | アップグレード | Citigroup | Neutral → Buy |
| 2022-08-15 | ダウングレード | CLSA | Buy → Outperform |
| 2022-08-12 | ダウングレード | Citigroup | Buy → Neutral |
| 2022-08-12 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2022-08-12 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-06-06 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-04-06 | 開始されました | Wolfe Research | Outperform |
| 2022-01-31 | アップグレード | Citigroup | Neutral → Buy |
| 2022-01-31 | アップグレード | Goldman | Neutral → Buy |
| 2022-01-28 | アップグレード | RBC Capital Mkts | Underperform → Sector Perform |
| 2022-01-24 | アップグレード | BofA Securities | Underperform → Neutral |
| 2022-01-24 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-01-13 | アップグレード | CLSA | Outperform → Buy |
| 2022-01-13 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2021-12-21 | アップグレード | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-12-06 | アップグレード | Macquarie | Neutral → Outperform |
| 2021-10-22 | アップグレード | CLSA | Underperform → Outperform |
| 2021-08-02 | ダウングレード | CLSA | Outperform → Sell |
| 2021-08-02 | ダウングレード | Needham | Buy → Hold |
| 2021-07-28 | アップグレード | Jefferies | Underperform → Hold |
| 2021-07-26 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2021-07-14 | 開始されました | RBC Capital Mkts | Underperform |
| 2021-06-28 | ダウングレード | Citigroup | Buy → Neutral |
| 2021-06-22 | アップグレード | Macquarie | Neutral → Outperform |
| 2021-06-22 | 開始されました | Robert W. Baird | Neutral |
| 2021-06-21 | 繰り返されました | Needham | Buy |
| 2021-06-16 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2021-06-09 | アップグレード | CLSA | Sell → Outperform |
| 2021-05-21 | アップグレード | JP Morgan | Neutral → Overweight |
| 2021-05-11 | アップグレード | Citigroup | Neutral → Buy |
| 2021-04-30 | ダウングレード | Citigroup | Buy → Neutral |
| 2021-03-16 | アップグレード | Needham | Hold → Buy |
| 2020-11-02 | アップグレード | UBS | Neutral → Buy |
| 2020-10-30 | アップグレード | JP Morgan | Underweight → Neutral |
| 2020-10-27 | アップグレード | BofA Securities | Underperform → Neutral |
| 2020-08-07 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-17 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-05-01 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2020-05-01 | アップグレード | Oppenheimer | Perform → Outperform |
| 2020-02-18 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-03 | 開始されました | CLSA | Underperform |
| 2020-01-31 | ダウングレード | UBS | Buy → Neutral |
| 2020-01-10 | 開始されました | Oppenheimer | Perform |
| 2019-11-22 | 開始されました | KeyBanc Capital Markets | Sector Weight |
| 2019-07-29 | アップグレード | UBS | Neutral → Buy |
| 2019-07-16 | ダウングレード | UBS | Buy → Neutral |
| 2019-05-06 | アップグレード | UBS | Neutral → Buy |
| 2019-04-18 | アップグレード | JP Morgan | Underweight → Neutral |
| 2019-01-25 | ダウングレード | Goldman | Buy → Neutral |
| 2019-01-25 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2018-10-26 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2018-07-02 | 開始されました | Goldman | Buy |
すべてを表示
Resmed Inc (RMD) 最新ニュース
Form 4 ResMed Inc For: 1 October By Investing.com - Investing.com Canada
A 10% dividend increase is part of ResMed (RMD)'s FY2027 stockholder return plan. - Stock Titan
Resmed to Report First Quarter Fiscal 2027 Earnings on October 29, 2026 - marketscreener.com
Start Your Engines for Sleep Education - homecaremag.com
Is the New Setup at ResMed (NYSE:RMD) Sustainable? - Kalkine Media
Operating margin % of ResMed Inc. CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh – HAN:RMEA - TradingView
ResMed Inc. (RMD) Stock Forecasts - Yahoo Finance
Can ResMed (ASX:RMD) Hit Its Outlook After Retiring the Astral Ventilator? - Kalkine Media
Is ResMed A Better Way Than Stryker To Own Medical Device Growth? - Trefis
ResMed Inc. (NYSE:RMD) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Stifel Maintains ResMed(RMD.US) With Hold Rating - Moomoo
ResMed stock trades at USD 221.89 after RBC target hike - AD HOC NEWS
ResMed stock heads into the open after September 24 data - AD HOC NEWS
Will ResMed (ASX:RMD) Keep Taking Share in Sleep Apnoea? - Kalkine Media
ResMed Inc. (RMD) Stock forecasts - Yahoo Finance UK
ResMed CEO Farrell: Every Hour of CPAP Use Cuts Healthcare Costs 7% - finance.biggo.com
What Is ResMed Signalling With Its Share Repurchase (ASX:RMD)? - Kalkine Media
ResMed stock reports 10 percent fiscal revenue growth - AD HOC NEWS
ResMed Inc. $RMD Shares Purchased by State Street Corp - MarketBeat
ResMed Inc. $RMD Shares Sold by Baird Financial Group Inc. - MarketBeat
ResMed stock slips 0.73 percent ahead of the open - AD HOC NEWS
ResMed stock targets 12 to 14 percent EPS growth - AD HOC NEWS
ResMed stock heads into the open after a 0.2 percent gain - AD HOC NEWS
How Is ResMed Reshaping What It Owns (ASX:RMD)? - Kalkine Media
ResMed Targets 12%-14% EPS Growth as GLP-1 Patients Lift Sleep Therapy Demand - MarketBeat
ResMed stock holds gains as analysts highlight sleep apnea growth - AD HOC NEWS
Weekly Recap: FY26 revenue & EPS growth and RBC upgrade, $1.5B buyback - TradingView
ResMed Inc. (RMD) Stock Analysis: A Healthcare Titan With A 10% Potential Upside - DirectorsTalk Interviews
ResMed Stock And Senior Healthcare Shares Linked To Medicare Spending Trends - simplywall.st
ResMed Inc. stock edges lower as analysts lift targets after recent results - AD HOC NEWS
ResMed stock gains on RBC upgrade and new institutional buying - AD HOC NEWS
ResMed Inc. stock gains on analyst upgrade and new investor interest - AD HOC NEWS
ResMed Inc. (RMD)’s Sleep Apnea Leadership Supports Growth Despite Rising Competitive Pressures - Yahoo Finance
Nykredit A S Makes New Investment in ResMed Inc. $RMD - MarketBeat
ResMed Inc. stock falls Friday, underperforms market - MarketWatch
Bank of America Corp DE Buys New Stake in ResMed Inc. $RMD - MarketBeat
ResMed Shares Jump Following RBC Capital Upgrade to Outperform - TIKR.com
Sleep Device Maker ResMed Gets an Upgrade. Analysts See a Lot to Like. - Barron's
ResMed stock jumps 3% on RBC Capital upgrade to Outperform - Investing.com
This Analyst Just Upgraded ResMed Stock. Here's Why. - Barchart.com
Why ResMed (RMD) Stock Is Up Today - Moomoo
Is Margin Pressure From Rising Costs Altering The Investment Case For ResMed (RMD)? - Yahoo Finance
Resmed Inc Stock (RMD) Moved Up by 3.05% on Sep 15: A Full Analysis - TradingKey
ResMed Projected to Attain High-Single-Digit EPS Growth in Next Three Years, RBC Says - marketscreener.com
ResMed Price Target Raised to $262.00/Share From $244.00 by RBC Capital - Moomoo
Is This the Right Time to Retain Resmed Stock in Your Portfolio? - Yahoo Finance
ResMed upgraded at RBC Capital Markets on Q4 positives - Seeking Alpha
RBC Capital Upgrades ResMed(RMD.US) to Buy Rating, Raises Target Price to $262 - Moomoo
Resmed Inc. : RBC Raises to Outperform From S - Moomoo
ResMed Stock: Is RMD Underperforming the Healthcare Sector? - finance.yahoo.com
ResMed Inc. (RMD) Stock Analysis: Exploring 12.90% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
Resmed Inc (RMD) 財務データ
収益
当期純利益
現金流量
EPS
1.92%
0.28%
大文字化:
|
ボリューム (24 時間):